Bayer EBIT 2010-2024 | BAYRY
Bayer ebit from 2010 to 2024. Ebit can be defined as earnings before interest and taxes.
Bayer Annual EBIT
(Millions of US $) |
| 2023 |
$662 |
| 2022 |
$7,388 |
| 2021 |
$3,967 |
| 2020 |
$-18,470 |
| 2019 |
$4,692 |
| 2018 |
$4,622 |
| 2017 |
$6,672 |
| 2016 |
$7,793 |
| 2015 |
$6,940 |
| 2014 |
$7,319 |
| 2013 |
$6,554 |
| 2012 |
$5,093 |
| 2011 |
$4,582 |
| 2010 |
$2,677 |
| 2009 |
$2,906 |
Bayer Quarterly EBIT
(Millions of US $) |
| 2024-06-30 |
$-1,030 |
| 2024-03-31 |
$3,357 |
| 2023-12-31 |
$2,425 |
| 2023-09-30 |
$-3,912 |
| 2023-06-30 |
$-1,042 |
| 2023-03-31 |
$3,191 |
| 2022-12-31 |
$1,274 |
| 2022-09-30 |
$1,208 |
| 2022-06-30 |
$180 |
| 2022-03-31 |
$4,727 |
| 2021-12-31 |
$2,373 |
| 2021-09-30 |
$625 |
| 2021-06-30 |
$-2,748 |
| 2021-03-31 |
$3,717 |
| 2020-12-31 |
$1,635 |
| 2020-09-30 |
$-10,987 |
| 2020-06-30 |
$-11,874 |
| 2020-03-31 |
$2,757 |
| 2019-12-31 |
$85 |
| 2019-09-30 |
$1,351 |
| 2019-06-30 |
$1,041 |
| 2019-03-31 |
$2,215 |
| 2018-12-31 |
$-4,971 |
| 2018-09-30 |
$5,143 |
| 2018-06-30 |
$1,611 |
| 2018-03-31 |
$2,839 |
| 2017-12-31 |
$203 |
| 2017-09-30 |
$1,631 |
| 2017-06-30 |
$2,366 |
| 2017-03-31 |
$2,472 |
| 2016-12-31 |
$798 |
| 2016-09-30 |
$2,003 |
| 2016-06-30 |
$2,415 |
| 2016-03-31 |
$2,576 |
| 2015-12-31 |
$916 |
| 2015-09-30 |
$1,741 |
| 2015-06-30 |
$2,028 |
| 2015-03-31 |
$2,255 |
| 2014-12-31 |
$600 |
| 2014-09-30 |
$1,826 |
| 2014-06-30 |
$2,021 |
| 2014-03-31 |
$2,873 |
| 2013-12-31 |
$916 |
| 2013-09-30 |
$1,617 |
| 2013-06-30 |
$1,681 |
| 2013-03-31 |
$2,339 |
| 2012-12-31 |
$934 |
| 2012-09-30 |
$1,049 |
| 2012-06-30 |
$964 |
| 2012-03-31 |
$2,146 |
| 2011-12-31 |
$378 |
| 2011-09-30 |
$1,427 |
| 2011-06-30 |
$1,507 |
| 2011-03-31 |
$1,220 |
| 2010-12-31 |
$-314 |
| 2010-09-30 |
$419 |
| 2010-06-30 |
$1,062 |
| 2010-03-31 |
$1,057 |
| 2009-12-31 |
$-82 |
| 2009-09-30 |
$1,199 |
| 2009-06-30 |
$829 |
| 2009-03-31 |
$1,097 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$0.000B |
$51.553B |
|
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
|
